Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
August 16 2023 - 3:10PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For
the month of August 2023
Commission
file number: 001-40231
Universe
Pharmaceuticals INC
265
Jingjiu Avenue
Jinggangshan
Economic and Technological Development Zone
Ji’an,
Jiangxi, China 343100
+86-0796-8403309
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Receipt
of Nasdaq Notification Regarding Compliance with Nasdaq Minimum Bid Price Requirement
As
previously disclosed, Universe Pharmaceuticals INC, an exempted company with limited liability formed in the Cayman Islands (the “Company”)
received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”)
on March 2, 2023, indicating that the Company was not in compliance with Nasdaq Rule 5450(a)(1) (the “Bid Price Rule”), as
the closing bid price for the Company’s ordinary shares had been below $1.00 per share for the preceding 30 consecutive business
days. In accordance with the Nasdaq Listing Rules, the Company was provided an initial period of 180 calendar days, or until August 29,
2023, to regain compliance with the Bid Price Rule.
On
August 14, 2023, the Company received a written notification from the Staff of Nasdaq, noting that the Company evidenced a closing bid
price of its ordinary shares at or greater than the $1.00 per share minimum requirement for the preceding 12 consecutive business days,
from July 28, 2023 through August 11, 2023, and informing the Company that it has regained compliance with the Bid Price Rule and the
matter is closed.
SIGNATURES
Pursuant
to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
|
Universe Pharmaceuticals INC. |
|
|
Date: August 16, 2023 |
By: |
/s/
Gang Lai |
|
|
Gang Lai |
|
|
Chief Executive Officer |
2
Universe Pharmaceuticals (NASDAQ:UPC)
Historical Stock Chart
From Nov 2024 to Dec 2024
Universe Pharmaceuticals (NASDAQ:UPC)
Historical Stock Chart
From Dec 2023 to Dec 2024